Iteos Therapeutics, INC 10-Q quarterly reports
Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.
iTeos Therapeutics reports significant losses and plans to wind down operations, entering a merger agreement with Concentra Biosciences for $10.047 cash plus a contingent value right per share.
iTeos Therapeutics announces its financial results for the first quarter of 2025, highlighting progress in its clinical programs and providing an update on its financial position.
iTeos Therapeutics reported a net loss of $45.4 million for the third quarter of 2024, while highlighting progress in its clinical programs and a $35 million milestone payment from GSK.
iTeos Therapeutics reports a net loss of $7.1 million for the three months ended June 30, 2024, but also recognizes $35 million in license and collaboration revenue due to a milestone achievement.
iTeos Therapeutics reported a net loss of $38.2 million for the first quarter of 2024, with ongoing clinical development programs and a recent $120 million capital raise.